“Expression of STAT3 in Prostate Cancer Metastases” Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R, Bjartell A. Eur Urol. 2017 Mar;71(3):313-316. doi: 10.1016/j.eururo.2016.06.018 (pubmed)

“Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer” Escobar Z, Bjartell A, Canesin G, Evans-Axelsson S, Sterner O, Hellsten R, Johansson MH. J Med Chem. 2016 May 26;59(10):4551-62. doi: 0.1021/acs.jmedchem.5b01814. (pubmed)

”The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” Canesin G, Evans-Axelsson S, Hellsten R, Sterner O, Krzyzanowska A, Andersson T, Bjartell A. Eur Urol. S0302-2838(15)00519-9. doi: 10.1016/j.eururo.2015.06.016 (pubmed)

”Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells” Don-Doncow, N. Escobar, Z. Johansson, M. Kjellstroem, S. Garcia, V. Munoz, E. Sterner, O. Bjartell, A. Hellsten, R. Journal of Biological Chemistry 2014 289 (23) 15969-15978 (pubmed)

”Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells”. Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A. PLoS One. 2011;6(7):e22118. doi: 10.1371/journal.pone.0022118 (pubmed)

”Tandem Pd-catalyzed carbonylation and intramolecular vinyl allene Diels-Alder reaction toward galiellalactone analogues”. Gidlöf R, Johansson M, Sterner O. Org Lett. 2010 12(22):5100-3. doi: 10.1021/ol101989m (pubmed)

”Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3”. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, Bjartell A. Prostate. 2008 68(3):269-80. doi: 10.1002/pros.20699. (pubmed)

”Synthesis of (-)-galiellalactone”. Johansson M, Sterner O. J Antibiot (Tokyo). 2002 55(7):663-5 (free full text)

”Synthesis of (+)-galiellalactone. Absolute configuration of galiellalactone”. Johansson M, Sterner O.Org Lett. 2001 3(18):2843-5. (pubmed)

Conference presentations

“New derivative of galiellalactone inhibits the STAT3 activity and suppresses ENZ-resistant Prostate Cancer in vitro” AACR, Philadelphia, Abstract number 728

“Preclinical characterization of GPA512: A prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer.” ASCO, Chicago, J Clin Oncol 32, 2014 (suppl; abstr e22186)

”Targeting STAT3 in prostate cancer: Identification of STAT3 as a direct target of the fungal metabolite galiellalactone” Nicholas Don-Doncow, Zilma Escobar, Martin Johansson, Eduardo Muñoz, Olov Sterner, Anders Bjartell, Rebecka Hellsten. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23 ,2013, Boston, MA. Abstract nr C229.